CHEK Stock Overview
Check-Cap Ltd., una empresa de diagnóstico médico en fase clínica, se dedica al desarrollo de una tecnología de cribado basada en cápsulas que utiliza rayos X de dosis ultrabaja para explorar el revestimiento interno del colon en busca de pólipos precancerosos y otras anomalías estructurales en Israel.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Check-Cap Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.59 |
| 52 Week High | US$4.63 |
| 52 Week Low | US$1.26 |
| Beta | 0.12 |
| 1 Month Change | 34.20% |
| 3 Month Change | 22.17% |
| 1 Year Change | 99.23% |
| 3 Year Change | -91.65% |
| 5 Year Change | -94.86% |
| Change since IPO | -99.81% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Check-Cap's (NASDAQ:CHEK) Cash Burn Rate
Jul 19
Here's Why We're Watching Check-Cap's (NASDAQ:CHEK) Cash Burn Situation
Feb 05We're Keeping An Eye On Check-Cap's (NASDAQ:CHEK) Cash Burn Rate
Sep 03Here's Why We're Not Too Worried About Check-Cap's (NASDAQ:CHEK) Cash Burn Situation
May 19We Think Check-Cap (NASDAQ:CHEK) Can Afford To Drive Business Growth
Feb 03We're Hopeful That Check-Cap (NASDAQ:CHEK) Will Use Its Cash Wisely
Oct 21Check-Cap (NASDAQ:CHEK) Is In A Good Position To Deliver On Growth Plans
Jul 01We're Keeping An Eye On Check-Cap's (NASDAQ:CHEK) Cash Burn Rate
Jan 02
Check Cap +1.5% on listing extension from NASDAQ
Dec 30Check-Cap EPS misses by $0.01
Nov 18Shareholder Returns
| CHEK | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -6.7% | -1.4% | -0.7% |
| 1Y | 99.2% | 7.4% | 25.9% |
Rentabilidad frente al sector: CHEK superó al sector US Medical Equipment , que obtuvo un rendimiento del 10.9% el año pasado.
Rentabilidad vs. Mercado: CHEK superó al mercado US, que obtuvo un rendimiento del 27.7% el año pasado.
Price Volatility
| CHEK volatility | |
|---|---|
| CHEK Average Weekly Movement | 12.4% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: El precio de las acciones de CHEK ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: CHEK(11%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de US.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 85 | Alex Ovadia | https://www.check-cap.com |
Check-Cap Ltd., una empresa de diagnóstico médico en fase clínica, se dedica al desarrollo de una tecnología de cribado basada en cápsulas que utiliza rayos X de dosis ultrabaja para escanear el revestimiento interno del colon en busca de pólipos precancerosos y otras anomalías estructurales en Israel. Su sistema C-Scan consta de C-Scan Cap, una cápsula de escaneado de rayos X para la detección de pólipos sospechosos; C-Scan Track, un sistema desechable fijado a la espalda del paciente mediante parches cutáneos adhesivos biocompatibles; y el software C-Scan View, una aplicación basada en cliente/servidor que permite la descarga de datos del procedimiento desde el C-Scan Track, el análisis de datos y la generación de informes. Check-Cap Ltd.
Check-Cap Ltd. Fundamentals Summary
| CHEK fundamental statistics | |
|---|---|
| Market cap | US$14.39m |
| Earnings (TTM) | -US$17.62m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs CHEK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHEK income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$17.62m |
| Earnings | -US$17.62m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.01 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CHEK perform over the long term?
See historical performance and comparison